1. Home
  2. ULBI vs ATOS Comparison

ULBI vs ATOS Comparison

Compare ULBI & ATOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ultralife Corporation

ULBI

Ultralife Corporation

HOLD

Current Price

$6.46

Market Cap

89.9M

Sector

Miscellaneous

ML Signal

HOLD

Logo Atossa Therapeutics Inc.

ATOS

Atossa Therapeutics Inc.

HOLD

Current Price

$5.30

Market Cap

83.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ULBI
ATOS
Founded
1990
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Miscellaneous
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
89.9M
83.3M
IPO Year
1992
2012

Fundamental Metrics

Financial Performance
Metric
ULBI
ATOS
Price
$6.46
$5.30
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$31.67
AVG Volume (30 Days)
51.9K
215.0K
Earning Date
03-10-2026
03-24-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.10
N/A
Revenue
$186,530,000.00
N/A
Revenue This Year
$31.30
N/A
Revenue Next Year
$6.24
N/A
P/E Ratio
$63.16
N/A
Revenue Growth
12.94
N/A
52 Week Low
$4.07
$4.91
52 Week High
$9.52
$19.35

Technical Indicators

Market Signals
Indicator
ULBI
ATOS
Relative Strength Index (RSI) N/A N/A
Support Level N/A N/A
Resistance Level N/A N/A
Average True Range (ATR) 0.00 0.00
MACD 0.00 0.00
Stochastic Oscillator 0.00 0.00

Price Performance

Historical Comparison
ULBI
ATOS

About ULBI Ultralife Corporation

Ultralife Corp provides products and services ranging from power solutions to communications and electronics systems to customers across the globe in the government and defense, medical, safety and security, energy, and industrial sectors. The company designs, manufactures, installs, and maintains power and communications systems including rechargeable and non-rechargeable batteries, charging systems, communications and electronics systems and accessories, and custom-engineered systems. The company's segments include Battery and Energy Products, and Communications Systems. It generates maximum revenue from the Battery and Energy Products segment, and from the U.S. The Battery & Energy Products segment includes Lithium 9-volt, cylindrical, and various other non-rechargeable batteries.

About ATOS Atossa Therapeutics Inc.

Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.

Share on Social Networks: